This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Merck agrees to buy cancer drugmaker Terns for $53 per share

( March 25, 2026, 14:26 GMT | Official Statement) -- MLex Summary: Merck intends to acquire oncology medicine creator Terns Pharmaceuticals for approximately $6.7 billion in equity value, or $53 a share, according to a corporate press release. Terns has a research pipeline drug for chronic myeloid leukemia, a slow-moving blood and bone marrow cancer that involves dysfunctional white blood cells, which often plague seniors.  “By working together, we will advance TERN-701, leveraging the deep expertise and signicant resources at Merck, a global biopharmaceutical leader with a proven track record of delivering cancer breakthroughs for patients who need them most," Terns CEO Amy Burroughs said.See attached document....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login